{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346888","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2026-08-12T20:15:36+00:00","discovered_at":"2026-08-12T20:17:00.192560+00:00","generated_at":"2026-08-12T20:17:18.394801+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atea reports Q2 net loss $32.9M; HCV Phase 3 C-BEYOND hits primary endpoint","bullets":["Net loss $32.9M ($0.41/sh) vs $37.2M ($0.44/sh) in Q2 2025; cash & investments $219.5M, down from $301.8M at year-end 2025.","C-BEYOND met primary non-inferiority endpoint: BEM/RZR SVR 93.9% vs SOF/VEL 94.8% in mITT (n=905); SVR 93.5% in non-cirrhotics with 8-week regimen.","C-FORWARD enrollment completed (880+ patients, 17 countries); topline expected early Q1 2027; NDA submission anticipated Q2 2027.","AT-587 Phase 1 trial initiated in July 2026 for hepatitis E virus; no approved HEV therapy exists.","R&D expenses $28.2M in Q2 2026, down from $32.3M year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346888","json":"https://secwatch.observer/filing/0001193125-26-346888.json","markdown":"https://secwatch.observer/filing/0001193125-26-346888.md","text":"https://secwatch.observer/filing/0001193125-26-346888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/0001193125-26-346888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:17:18.394801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}